fda compounding semaglutide crackdown november 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Drug compounders sue FDA over

With traditional semaglutide injections, some patients experience stomach-related side effects, such as nausea

Whilst the theoretical benefits of GLP-1 receptor agonists in inflammatory conditions are being explored in research settings, patients considering this approach must understand both the potential advantages and significant risks associated with off-label use

Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis

GSH is detected in high concentrations in the extracellular epithelial lining fluid of the lower respiratory tract of healthy subjects, and could act as a first-time scavenger of toxic oxygen intermediates and protect against lung cell damage and injury